Efficacy Studies Not Enough? Consider GSK's Salford Lung Study As New Model
Executive Summary
Full results from asthma patients included in the Salford Lung Study provide powerful support for the use of “real world” effectiveness studies as a more relevant form of evidence to inform prescribing choices and improve patient outcomes, particularly in what turned out to be a general population of asthmatics that were still suffering symptoms under usual care.
You may also be interested in...
Randomized Study Objectives Should Drive Choice Of Real-World Data Sources, Experts Say
Start with the trial’s primary objective and then figure out which RWD sources could help inform that outcome, experts say at Duke-Margolis meeting; however, design and underlying objectives of Novo Nordisk’s real-world use of trial of Ozempic have the FDA’s Robert Temple suggesting success will be a ‘longshot.’
Manchester United With Big Pharma On Improving Outcomes
The English city's desire to collaborate with the pharmaceutical industry to come up with cost-effective solutions to treat long-term chronic diseases has seen Manchester emerge as a closely watched experiment for the future of health care.
Target's NASH Study Captures Real World Data, Helps Partners With Trial Design
Longitudinal observational study of NASH patients provides data to companies to help them better understand disease; Target PharmaSolutions conducting similar efforts in primary biliary cholangitis, hepatocellular carcinoma, and inflammatory bowel disease.